美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

The Nightview Fund

39.65

+0.27000.69%

盤後：39.650.00000.00%19:30 EDT

成交量：120

成交額：4,759.66

市值：3,424.97萬

市盈率：- -

高：39.65

開：39.65

低：39.65

收：39.38

52周最高：41.00

52周最低：32.61

股本：86.38萬

流通股本：86.38萬

量比：0.03

換手率：0.01%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

新股消息｜FronteraTherapeutics再次遞表港交所，深耕rAAV眼科基因治療賽道

新股消息｜FronteraTherapeutics再次遞表港交所，深耕rAAV眼科基因治療賽道

REGENXBIO股價盤前下跌25%，因美國FDA暫停該公司針對亨特綜合徵的基因療法臨床試驗。

火箭實驗室加入美國太空部隊價值 9.81 億美元的 NITE‑STAR 項目，推進太空測試與訓練基礎設施建設。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/NITE/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NITE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NITE\",,,,,undefined,":{"symbol":"NITE","market":"US","secType":"STK","nameCN":"The Nightview Fund","latestPrice":39.65,"timestamp":1789156800000,"preClose":39.38,"halted":0,"volume":120,"hourTrading":{"tag":"盘后","latestPrice":39.65,"preClose":39.65,"latestTime":"19:30 EDT","volume":9,"amount":356.85,"timestamp":1789169407249,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.00685627221940061,"floatShares":863800,"shares":863800,"eps":0,"marketStatus":"休市中","change":0.27,"latestTime":"09-11 16:00:00 EDT","open":39.65,"high":39.65,"low":39.65,"amount":4759.66368,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":1506571200000,"exchange":"ARCA","adjPreClose":39.38,"sharesOutstanding":943768,"nav":39.59,"aum":34198646.29,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.65,"preClose":39.65,"latestTime":"19:30 EDT","volume":9,"amount":356.85,"timestamp":1789169407249,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.02997152660015695},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NITE\",,,,,undefined,":{"symbol":"NITE","floatShares":863800,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.02997152660015695,"shares":863800,"dividePrice":0,"high":39.65,"amplitude":0,"preClose":39.38,"low":39.65,"week52Low":32.6117,"pbRate":"--","week52High":41.004,"institutionHeld":0,"latestPrice":39.65,"eps":0,"divideRate":0,"volume":120,"delay":0,"ttmEps":0,"open":39.65,"prevYearClose":36.612,"prevWeekClose":40.3768,"prevMonthClose":40.7518,"prevQuarterClose":36.9667,"fiveDayClose":41.004,"twentyDayClose":40.076,"sixtyDayClose":37.1564},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NITE\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NITE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NITE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NITE\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663045518","title":"新股消息｜FronteraTherapeutics再次遞表港交所，深耕rAAV眼科基因治療賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2663045518","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663045518?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 09:27","pubTimestamp":1788053221,"startTime":"0","endTime":"0","summary":"　　据招股书，该公司于2019年注册成立，是一家临床阶段基因疗法公司，致力于自主开发重组腺相关病毒基因疗法。Frontera公司的管线尤其专注于眼科及心血管疾病。　　截至最后实际可行日期，有超过 250 种在研 rAAV 基因治疗药物，其中五种处于 BLA 阶段。罕见病及眼科疾病占全球 rAAV 基因治疗管线的大部分。罕见病治疗占所有在研 rAAV 基因治疗药物的一半以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260830/32353638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["NITE","HEXmain","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663045362","title":"新股消息｜FronteraTherapeutics再次遞表港交所，深耕rAAV眼科基因治療賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2663045362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663045362?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 08:51","pubTimestamp":1788051069,"startTime":"0","endTime":"0","summary":"Frontera公司的管线尤其专注于眼科及心血管疾病。截至最后实际可行日期，FronteraTherapeutics 尚未取得任何候选药物的上市批准，也未从产品销售中产生任何收入。罕见病及眼科疾病占全球rAAV基因治疗管线的大部分。罕见病治疗占所有在研rAAV基因治疗药物的一半以上。董事会资料FronteraTherapeutics 董事会由九名董事组成，包括一名执行董事、五名非执行董事及三名独立非执行董事。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NITE","HEXmain","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661759472","title":"REGENXBIO股價盤前下跌25%，因美國FDA暫停該公司針對亨特綜合徵的基因療法臨床試驗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2661759472","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661759472?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:42","pubTimestamp":1787571759,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NITE","LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660378334","title":"火箭實驗室加入美國太空部隊價值 9.81 億美元的 NITE‑STAR 項目，推進太空測試與訓練基礎設施建設。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660378334","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660378334?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 05:11","pubTimestamp":1787001077,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4550","AIRR","XLI","HWAY","NFRX","BK4585","XLII","NITE","MADE","BK4588","PRN","BK4581"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}